Opinion|Videos|March 3, 2025
The Impact of Biologics on a Changing Atopic Dermatitis Treatment Landscape
Panelists discuss how the emergence of targeted biologics has revolutionized atopic dermatitis treatment by offering effective alternatives to traditional therapies. These agents, including IL-4/IL-13 inhibitors like dupilumab and others targeting specific inflammatory pathways, have provided new options for moderate to severe cases resistant to conventional treatments.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- How has the development and approval of several biologics changed the treatment spectrum for atopic dermatitis?
Advertisement
Related to this article
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
4
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
5